Salt Lake City, UT (PRWEB) June 12, 2015 -- Co-Diagnostics today announced the launch of its India TB initiative - to provide affordable, state-of-the-art qPCR tests for tuberculosis. Thousands of Co-Diagnostics’ TB tests, to be performed on Life Technologies Step One devices, have been deployed by Mapmygenome, Hyderabad. Co-Diagnostics and Mapmygenome personnel will be training Indian lab technicians in the company’s test protocols. It is expected that the initiative will quickly expand to labs throughout the country.
Co-Diagnostics has developed a proprietary, mathematically-based test platform, greatly facilitating the rapid development of highly accurate, affordable DNA and RNA tests for the detection of infectious disease. The company anticipates price points for its tests that will be low enough to facilitate broad, affordable TB testing of the Indian population.
India has the highest tuberculosis burden in the world, with approximately 1,000 daily deaths attributed to the disease. Co-Diagnostics CEO Dwight Egan noted, “Accurate, low-cost, DNA-based diagnostics for tuberculosis will be critical to reversing India’s challenging disease and mortality rate. Up to 40% of the Indian population has inactive - or latent - tuberculosis, and about 10% will evolve into active cases during their lifetimes. Our objective is to make the very best TB tests widely available in India, incorporating our unique and highly effective molecular diagnostics technology.”
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develop and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.
Dwight Egan, Co Diagnostics, Inc., http://www.codiagnostics.com, +1 (801) 438-1036, [email protected]
Share this article